E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Macrophage activation syndrome (MAS) in the context of Systemic juvenile inflammatory arthritis (sJIA) and Adult onset Still’s disease (AOSD). MAS in the context of pediatric and adult Systemic lupus erythematosus (SLE). |
|
E.1.1.1 | Medical condition in easily understood language |
Children and adults with macrophage activation syndrome (MAS) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10071583 |
E.1.2 | Term | Haemophagocytic lymphohistiocytosis |
E.1.2 | System Organ Class | 10021428 - Immune system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate efficacy of emapalumab in the treatment of patients in: - Cohort 1: MAS in the context of systemic juvenile idiopathic arthritis and adult onset Still’s disease (AOSD). - Cohort 2: MAS in the context of pediatric and adult systemic lupus erythematosus (SLE). |
|
E.2.2 | Secondary objectives of the trial |
To demonstrate efficacy of emapalumab with respect to tapering of glucocorticoids (GCs). To evaluate the time to onset of response to emapalumab treatment. To evaluate efficacy of emapalumab with respect to overall response. To evaluate the sustained efficacy of emapalumab treatment. To evaluate the patient´s survival after treatment of emapalumab. To evaluate the safety and tolerability of emapalumab. To evaluate subject reported outcome of MAS in patients treated with emapalumab. To determine the pharmacokinetic (PK) profile of emapalumab. To determine the pharmacodynamic (PD) profile of emapalumab. To determine the immunogenicity of emapalumab |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Run-in phase in all cohorts 1. Informed consent provided by the subject or by the subject's legally authorized representative(s) with the assent of subjects who are legally capable of providing it, as required by local law. 2. Male and female subjects aged between 6 months and 80 years of age at the time of diagnosis of MAS. 3. MAS defined as per the criteria defined below for each cohort and requiring treatment with GCs as per standard of care. Interventional phase in all cohorts 1. Informed consent provided by the subject or by the subject’s legally authorized representative(s) with the assent of subjects who are legally capable of providing it, as as required by local law. 2. Male and female subjects aged between 6 months and 80 years of age at the time of diagnosis of active MAS. 3. Subjects who have shown an inadequate response to high dose intravenous (i.v.) GCs administered for at least 3 days according to local standard clinical practice, including but not limited to pulses of 30 mg/kg methylprednisolone (mPDN)on 3 consecutive days. High i.v. GCs dose is recommended not to be lower than 2 mg/kg/ day PDN equivalent (or at least 60 mg/day in pediatric subjects of 30 kg or more, and at least 1g/day in adult MAS subjects). In case of rapid worsening of the subject’s condition and/or laboratory parameters, as per Investigator judgment, inclusion may occur within less than 3 days from starting high dose GCs. 4. Diagnosis of active MAS confirmed by the treating rheumatologist, having ascertained the followings: a. Febrile subjects presenting with ferritin > 684 ng/mL. b. and any 2 of: i. Platelet count ≤ 181 x109/L ii. AST-level > 48 U/L iii. Triglycerides > 156 mg/dL iv. Fibrinogen level ≤ 360 mg/dL 5. Female patients of child-bearing potential (sexually or non-sexually active). Female patients who are sexually active must be willing to use highly effective methods of contraception from study drug initiation to 6 months after the last dose of study drug. Specific inclusion criteria to Cohort 1 and Cohort 2 6. Cohort 1: a. Confirmed sJIA diagnosis. For subjects presenting with MAS in the context of the onset of sJIA, high presumption of sJIA will suffice for eligibility. b. Confirmed diagnosis of AOSD as per Yamaguchi criteria (Yamaguchi et al. 1992). 7. Cohort 2: a. Confirmed diagnosis of SLE as per Systemic Lupus International Collaborating Clinics (SLICC) 2012 criteria. |
|
E.4 | Principal exclusion criteria |
1. Primary hemophagocytic lymphohistiocytosis (p-HLH) documented by either the presence of a known causative genetic mutation or abnormal perforin expression and CD107a degranulation assay as described with primary hemophagocytic lymphohistiocytosis or by the presence of family history. 2. Confirmed malignancy. Note: subjects with a suspected malignancy should have mononuclaear cells typed by flow cytometry and/or tissue biopsy, as applicable, to rule out malignancy. 3. Treatment with canakinumab, JAK inhibitors, TNF inhibitors and tocilizumab at the time of emapalumab initiation. 4. Ongoing treatment with anakinra at a dose above 4 mg/kg at time of emapalumab initiation. 5. Patients treated with etoposide for MAS in the last 1 month. 6. Presence of any medical or psychological condition or laboratory result that in the opinion of the Investigator can interfere with the patient's ability to comply with the protocol requirements or makes the patient not appropriate for inclusion to the study and treatment with emapalumab. 7. Foreseeable inability to cooperate with given instructions or study procedures. 8. Clinically active mycobacteria (typical and atypical), Histoplasma Capsulatum, or Salmonella infections. 9. Evidence of leishmania infections. 10. Evidence of latent tuberculosis. 11. History of hypersensitivity or allergy to any component of the study drug. 12. Receipt of a Bacillus Calmette-Guerin (BCG) vaccine within 12 weeks prior to screening. 13. Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screening. 14. Pregnancy or lactating female patients. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of subjects with complete response (CR) at Week 8 after first administration of emapalumab.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
GCs tapering to a dose below 50 % of prednisolone (PDN) equivalent at the time of emapalumab start or to the same (or lower) dose being administered before the occurrence of MAS (in subjects already treated for the underlying condition) whichever occurs first at any time during the study. GCs tapering to ≤1mg/kg/day of PDN equivalent at any time during the study. Time to achieve GCs tapering as described above . Time to first CR. Proportion of subjects with overall response as defined by CR or PR (partial response). Time to first overall response as defined by CR or PR. MAS recurrence at any time after achievement of CR. Withdrawal from the study due to lack of response as per Investigator decision. Survival time. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 19 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
China |
Japan |
Russian Federation |
United Kingdom |
United States |
Belgium |
Czechia |
France |
Germany |
Italy |
Netherlands |
Poland |
Spain |
Sweden |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 28 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |